Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C13H12N8O4S3 |
Molecular Weight | 440.481 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12SCC(CSC3=NN=CS3)=C(N1C(=O)[C@H]2NC(=O)CN4C=NN=N4)C(O)=O
InChI
InChIKey=DZMVCVMFETWNIU-LDYMZIIASA-N
InChI=1S/C13H12N8O4S3/c22-7(1-20-4-14-18-19-20)16-8-10(23)21-9(12(24)25)6(2-26-11(8)21)3-27-13-17-15-5-28-13/h4-5,8,11H,1-3H2,(H,16,22)(H,24,25)/t8-,11-/m1/s1
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/17671744Curator's Comment: Description is created based on several sources, including http://aksci.com/item_detail.php?cat=H709 and http://www.ncbi.nlm.nih.gov/pubmed/994325
Sources: http://www.ncbi.nlm.nih.gov/pubmed/17671744
Curator's Comment: Description is created based on several sources, including http://aksci.com/item_detail.php?cat=H709 and http://www.ncbi.nlm.nih.gov/pubmed/994325
Ceftezole sodium is a cephalosporin antibiotic. Ceftezole was found to be a broad-spectrum antibiotic, active in vitro against many species of gram-positive and gram-negative bacteria except Pseudomonas aeruginosa, Serratia marcescens and Proteus vulgaris. Ceftezole sodium is used as an injectable or through an intravenous mode of delivery. The bactericidal activity of ceftezole results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). The PBPs are transpeptidases which are vital in peptidoglycan biosynthesis. Therefore, their inhibition prevents this vital cell wall component from being properly synthesized. Ceftezole has been shown to exhibit potent alpha-glucosidase inhibitory activity. In in vitro alpha-glucosidase assays, ceftezole was shown to be a reversible, non-competitive inhibitor of yeast alpha-glucosidase with a Ki value of 5.78 x 10(-7) M when the enzyme mixture was pretreated with ceftezole. Ceftezole is used for the treatment of susceptible bacterial infections including septicemia, respiratory, biliary or GU tract, skin and skin structure, endocarditis. Surgical prophylaxis.
Originator
Sources: http://www.google.dj/patents/CN102775426A?cl=en
Curator's Comment: Ceftezole sodium injection is a first-generation cephalosporin, developed by the Japanese company Fujisawa
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2932 Sources: http://www.ncbi.nlm.nih.gov/pubmed/17671744 |
2.1 µM [IC50] | ||
Target ID: map00550 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D01517 |
|||
Target ID: E. coli growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/994325 |
|||
Target ID: Klebsiella spp. growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/994325 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Ceftezole sodium for injection Approved UseIndicated for the treatment of septicaemia, pneumonia, bronchitis, bronchiectasis, secondary infection and chronic respiratory diseases, pulmonary abscess, peritonitis, pyelonephritis, cystitis and urethritis |
|||
Curative | Ceftezole sodium for injection Approved UseIndicated for the treatment of septicaemia, pneumonia, bronchitis, bronchiectasis, secondary infection and chronic respiratory diseases, pulmonary abscess, peritonitis, pyelonephritis, cystitis and urethritis |
|||
Curative | Ceftezole sodium for injection Approved UseIndicated for the treatment of septicaemia, pneumonia, bronchitis, bronchiectasis, secondary infection and chronic respiratory diseases, pulmonary abscess, peritonitis, pyelonephritis, cystitis and urethritis |
|||
Curative | Ceftezole sodium for injection Approved UseIndicated for the treatment of septicaemia, pneumonia, bronchitis, bronchiectasis, secondary infection and chronic respiratory diseases, pulmonary abscess, peritonitis, pyelonephritis, cystitis and urethritis |
Sample Use Guides
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/994325
Susceptibilities of 48 clinical isolates of S. aureus to ceftezole showed a peak at 0.20 ug/ml and no resistant strain with an MIC of 3.13 ug/ml or above was observed.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QJ01DB12
Created by
admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
|
||
|
WHO-ATC |
J01DB12
Created by
admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
|
||
|
NCI_THESAURUS |
C357
Created by
admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID0022771
Created by
admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
|
PRIMARY | |||
|
DB13821
Created by
admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
|
PRIMARY | |||
|
C76038
Created by
admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
|
PRIMARY | |||
|
561
Created by
admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
|
PRIMARY | |||
|
CHEMBL1697829
Created by
admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
|
PRIMARY | |||
|
2Z86SYP11W
Created by
admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
|
PRIMARY | |||
|
C012811
Created by
admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
|
PRIMARY | |||
|
26973-24-0
Created by
admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
|
PRIMARY | |||
|
CEFTEZOLE
Created by
admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
|
PRIMARY | |||
|
m1061
Created by
admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000081853
Created by
admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
|
PRIMARY | |||
|
135716
Created by
admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
|
PRIMARY | |||
|
SUB07424MIG
Created by
admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
|
PRIMARY | |||
|
3914
Created by
admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
|
PRIMARY | |||
|
65755
Created by
admin on Fri Dec 15 16:34:59 GMT 2023 , Edited by admin on Fri Dec 15 16:34:59 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)